• In particular, vaccines targeting oncogenic viruses, such as the human papillomavirus and the hepatitis B virus, are exceptional examples of successful prevention of virus-associated cancers, such as cervical cancer and hepatocellular carcinoma. (jci.org)
  • Human papilloma viruses (HPVs) are a small group of nonenveloped viruses belonging to the Papillomaviridae family with strong similarities to polyoma viruses. (phmj.org)
  • HPV vaccines protect against two to seven high-risk strains of this family of viruses and may prevent up to 90% of cervical cancers. (wikipedia.org)
  • Human papillomavirus (HPV) is one of the most common sexually transmitted viruses, affecting 50% of sexually active individuals at least once in their lifetime [ 1 ]. (biomedcentral.com)
  • CoviVac-Russia COVID-19 Vaccine is a Whole-virion vaccine that uses viruses that have already been killed (inactivated). (precisionvaccinations.com)
  • Examples of retroviruses are the human immunodeficiency viruses and the human T-cell leukemia viruses. (msdmanuals.com)
  • The viruses including human papilloma viruses (HPVs), Epstein-Barr virus (EBV-also known as human herpes virus type 4), mouse mammary tumor virus (MMTV), bovine leukemia virus (BLV), and human cytomegalovirus (HCMV) have been mentioned to be related to breast cancer [7]. (waocp.com)
  • Recognizing that these factors were impeding the broad use of HPV vaccination in low and middle-income countries, Merck & Co. Inc pledged to donate Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] to eligible income countries through the Gardasil Access Program (GAP). (biomedcentral.com)
  • Cervarix is a non-infectious recombinant, AS04-adjuvanted vaccine, that contains recombinant L1 protein, the major antigenic protein of the capsid, of oncogenic HPV types 16 and 18. (precisionvaccinations.com)
  • Human papillomavirus (HPV) vaccines are primarily designed to prevent HPV-associated cancers that typically occur years to decades after exposure to HPV-16 and -18. (cdc.gov)
  • The bivalent vaccine protects against HPV-16 and -18, the most common oncogenic HPV types, which are responsible for ≈70% of HPV-associated cervical cancers and a large proportion of other HPV-related cancers ( 1 ). (cdc.gov)
  • In the United States, type-specific HPV infection and genital warts are being monitored in a variety of settings to evaluate the earliest evidence of vaccine effect, and HPV-associated cancers are monitored through the National Cancer Institute's Surveillance, Epidemiology, and End Results program and the Centers for Disease Control and Prevention (CDC)-administered National Program of Cancer Registries, which cover the entire US population ( 8 , 9 ). (cdc.gov)
  • In particular, human papillomavirus types 16 and 18 are associated with 70% of cervical cancers, 3 whereas 90% of anogenital warts are linked to human papillomavirus types 6 and 11. (bmj.com)
  • Our model considers the impact of vaccination on squamous cell carcinomas, adenocarcinomas, cervical cancers due to high risk human papillomavirus types not in the vaccine, non-cervical cancers, and anogenital warts. (bmj.com)
  • Vaccination against human papillomavirus (HPV) is recommended to prevent new HPV infections and HPV-associated diseases, including some cancers. (cdc.gov)
  • Persistent infections with high-risk (oncogenic) HPV types can lead to development of cervical, anal, penile, vaginal, vulvar, and oropharyngeal cancers, usually after several decades ( 1 ). (cdc.gov)
  • The majority of HPV-associated cancers are caused by HPV 16 or 18, types targeted by all three vaccines. (cdc.gov)
  • In the early 1980s in the laboratory of later Nobel Prize laureate Harald zur Hausen he was the first (together with the postgraduates Matthias Dürst and Michael Boshart supervised by him) to isolate and characterize HPV16 and HPV18, the two most oncogenic HPV types causing the vast majority of HPV-induced anogenital and head-and-neck cancers. (wikipedia.org)
  • This groundbreaking work of Lutz Gissmann provided experimental evidence for the causal association of specific HPV types with human cancer, and laid the foundation for the development of prophylactic HPV vaccines for the prevention of cervical cancer and other HPV-induced cancers. (wikipedia.org)
  • The introduction of HPV vaccines has also drawn more attention to the fact that HPV is associated not only with cervical cancer and genital warts but also with other tumors, such as head neck and anogenital cancers ( 3 ). (cdc.gov)
  • Over 200 human papillomavirus (HPV) types, which are members of five genera ( α, β, γ, μ, v ) [ 1 , 2 ], are responsible for approximately 5% of all human cancers and substantial precancerous and benign lesions [ 3 , 4 ]. (oncotarget.com)
  • The preventive effect of HPV vaccines against anogenital and oropharyngeal cancers has been proven in both clinical trials and real-world data. (mdpi.com)
  • Infection with HPV is associated with 7-8% of all human malignancies and accountable for 96% of cervical cancer, 93% of anal cancers, 64% of vaginal cancers, 51% of vulvar cancer, 36% of penile cancers, and 63% of oropharyngeal carcinomas [ 2 ]. (biomedcentral.com)
  • Infection with Human Papillomavirus (HPV) "is estimated to cause […] 100% of cervical cancer cases," and contributes to the incidence of other cancers affecting both women and men, including anal cancer, oral and oropharyngeal cancers, and cancers of the genitals (WHO, 2008b). (medscinet.com)
  • The Section of Infections (INF) has diagnosis of human cancers driven by Correspondingly, ICE research includes two groups: the Infections and Cancer infections (Amorrortu et al. (who.int)
  • 2021). research, from etiology or natural history aim to evaluate the role of infectious through global burden assessment to agents in human cancers through biolog- The overall strategy of ICE is to improve evaluation and model ing of the impact of ical and epidemiological studies. (who.int)
  • Human papillomaviruses (HPVs) cause virtually all cervical cancers, the second leading cause of death by cancer among women, as well as other anogenital cancers and a subset of head and neck cancers. (virosin.org)
  • In this review, we summarize some recent findings on HPV-associated carcinogenesis, such as miRNAs in HPV-associated cancers, implication of stem cells in the biology and therapy of HPV-positive cancers, HPV vaccines, targeted therapy of cervical cancer, and drug treatment for HPV-induced intraepithelial neoplasias. (virosin.org)
  • Background Human papillomavirus (HPV) DNA is present in the majority of squamous cell cancers of the anus. (researchgate.net)
  • ISA Pharmaceuticals B.V. , a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the publication of a new peer-reviewed paper* demonstrating a beneficial effect of Synthetic Long Peptide (SLP®s) immunotherapeutics on intratumoral macrophages in cancers induced by human papilloma virus 16 (HPV16). (akampion.com)
  • Vaccination against human papillomavirus (HPV) is routinely recommended at age 11 or 12 years. (cdc.gov)
  • A new study by researchers from the International Agency for Research on Cancer (IARC), in collaboration with the Ministry of Health of Rwanda and partner institutions, has shown that vaccination against human papillomavirus (HPV) has more than halved the prevalence of high-risk HPV types in Rwanda in less than 8 years. (who.int)
  • Preventive screening programmes and vaccination against human papillomavirus (HPV) result in reduced cancer incidence and mortality. (prescriptec.org)
  • The quadrivalent vaccine also protects against HPV-16 and -18 and against HPV-6 and -11, two nononcogenic HPV types that cause genital warts and respiratory papillomatosis ( 2 ). (cdc.gov)
  • After licensure of the bivalent vaccine against HPV-16 and -18 in 2009, the ACIP guidelines for vaccination of women and girls were expanded to recommend quadrivalent or bivalent vaccine for protection against HPV types that can cause cancer. (cdc.gov)
  • Current research has focused on the determinants of infection with oncogenic HPV types, the assessment of prophylactic and therapeutic vaccines and the development of screening strategies incorporating HPV testing and other methods as adjunct to cytology. (cmaj.ca)
  • A bivalent vaccine with the same efficacy against human papillomavirus types 16 and 18 costing £13-£21 less per dose (depending on the duration of vaccine protection) may be as cost effective as the quadrivalent vaccine although less effective as it does not prevent anogenital warts. (bmj.com)
  • 5 Two prophylactic vaccines against human papillomavirus (a bivalent vaccine against types 16 and 18 and a quadrivalent vaccine that also includes types 6 and 11) have been shown to be efficacious in up to five years of follow-up against types 16 and 18 cervical infection and associated disease as well as against anogenital warts. (bmj.com)
  • 6 7 In addition, the results from clinical trials suggest that both vaccines may offer partial protection against oncogenic human papillomavirus types not in the vaccine. (bmj.com)
  • BACKGROUND: Persistent infection with high-risk types of human papillomavirus (HPV) is the preeminent factor driving the development of cervical cancer. (bvsalud.org)
  • There are many HPV types, some of which cause cancer (oncogenic) and others of which cause noncancerous disease (nononcogenic verruca vulgaris and condyloma acuminata). (hivguidelines.org)
  • In many countries, vaccines against some human papillomavirus (HPV) types are now administered to girls and young women with the goal of protecting them against HPV-induced cervical cancer ( 1 , 2 ). (cdc.gov)
  • A nonavalent vaccine (Gardasil 9) is currently in production which will provide an even greater degree of protection (against 9 HPV types instead of 4: HPV 6/11/16/18/31/33/45/52/58). (nursinginpractice.com)
  • Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant genital ( cervical, vulvar and vaginal) lesions and cervical cancer causally related to certain oncogenic human papillomavirus (HPV) types. (europa.eu)
  • Although the strategy of ICE is risk (HR) HPV infection in the etiology of beta human papillomavirus (HPV) types global, work is natural y focused on low- head and neck cancer. (who.int)
  • Vaccination against oncogenic HPV types is also deemed effective in preventing cervical cancer cases [8]. (clinomicseurope.com)
  • Background The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women in that they were 'negative to 14 HPV types' and in a m. (ccb.org.co)
  • A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions por: Kjaer, Susanne K., et al. (ccb.org.co)
  • In addition, we will appraise new approaches using "vaccine-omics" to discover novel types of adjuvants. (smw.ch)
  • Most human papillomavirus (HPV) surveillance studies target 30-50 of the more than 200 known types. (cdc.gov)
  • The identification of high-risk human papillomavirus (hrHPV) types (the cause of cervical cancer) offers the prospect of improving cervical screening programmes through the introduction of hrHPV-based screening tests. (samj.org.za)
  • More than 95% of most cervical malignancies are connected with and due to the Individual papillomavirus (HPV) (1 2 a breakthrough that resulted in Dr. oncogenic HPV types. (cell-metabolism.com)
  • Since June 2006, the Advisory Committee on Immunization Practices (ACIP) has recommended routine HPV vaccination of girls 11-26 or 12-26 years of age who have not previously been administered the quadrivalent vaccine ( 4 ). (cdc.gov)
  • To date, the quadrivalent vaccine accounts for almost all HPV vaccines distributed ( 6 ). (cdc.gov)
  • Health professionals represent, The primary prevention represented by condom use in some studies, the main providers of advice and a quadrivalent vaccine for HPV, as well as the on the vaccine. (bvsalud.org)
  • Parents may decide not to allow their daughters vaccine have reported reduction of precursor lesions to be vaccinated, based on cultural or religious from 60-80%, with rates of 100% in populations perceptions, and the unsubstantiated correlation vaccinated with the quadrivalent vaccine (6, 11, 16 of the vaccine facilitating early sexual activity12,13. (bvsalud.org)
  • The Work Group evaluated the quality of evidence for efficacy, safety, and effectiveness for HPV vaccination for primary prevention of HPV infection and HPV-related disease using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach ( https://www.cdc.gov/vaccines/acip/recs/grade/about-grade.html ). (cdc.gov)
  • Despite the clinical efficacy of recently developed polyvalent prophylactic HPV vaccines, these preventive measures are not effective against pre-existing infections. (archivog.com)
  • Clinical and epidemiological correlates of antibody response to human papillomaviruses (HPVs) as. (sagepub.com)
  • Human papillomavirus (HPV) infection is now recognized as the main cause of cervical cancer, the role of coexisting factors is better understood, a new cytology reporting terminology has improved diagnosis and management of precursor lesions, and specific treatment protocols have increased survival among patients with early or advanced disease. (cmaj.ca)
  • HPV infections can almost be eliminated through high coverage of HPV vaccination, and because oncogenic HPV infection is the necessary cause of cervical cancer, HPV elimination is the route to cervical cancer elimination. (who.int)
  • 63% were aware that infection is the most common cause of cervical cancer of these 49% said that virus is the cause and 16% of the respondents knew that the virus is Human Papilloma virus(HPV). (ijcrr.com)
  • The prevention, with early detection and health prevalence of high-risk oncogenic HPV in specific promotion essential in addressing the problem1,2. (bvsalud.org)
  • In 2007, five Emerging Infections Program (EIP) sites were funded to determine the feasibility of establishing a population-based surveillance system for monitoring the effect of human papillomavirus (HPV) vaccine on pre-invasive cervical lesions. (cdc.gov)
  • Human papillomaviruses are responsible for nearly 3000 cases of cervical cancer 1 and more than 100 000 diagnosed cases of anogenital warts 2 in the United Kingdom every year, despite a decrease in the incidence of cervical cancer as a result of regular cytological screening. (bmj.com)
  • We used a transmission dynamic model to predict the burden of human papillomavirus related disease for the number of cervical screens, treatments for precancerous abnormalities of the cervix, and cases of diagnosed cancer and anogenital warts expected before and after vaccination. (bmj.com)
  • Treatment is not recommended for subclinical anogenital or mucosal human papillomavirus (HPV) infection in the absence of coexistent dysplasia. (medscape.com)
  • Cancer-preventive vaccines targeting nonviral antigens, such as tumor-associated antigens and neoantigens, are also being extensively tested. (jci.org)
  • Until recently, prevention of human immunodeficiency virus (HIV) infection was unlikely to factor in the decision to circumcise a male newborn or child, although other preventive health benefits of male circumcision may have been considered. (cdc.gov)
  • The development of a prophylactic vaccine to prevent infection with oncogenic subtypes of human papillomavirus (HPV) is an important step in reducing cervical cancer incidence and mortality. (aacrjournals.org)
  • The same cost effectiveness model was later used to inform the adjudication process between the two vaccines, which led to a decision to use the bivalent vaccine in the UK immunisation programme. (bmj.com)
  • Cuba COVID-19 vaccine is a conjugate vaccine in which the virus antigen, the receptor-binding domain, is chemically bound to the tetanus toxoid. (precisionvaccinations.com)
  • This review discusses not only the mechanisms underlying persistent HPV infection but also the prospect of immunomodulatory therapeutic vaccines and small molecule inhibitors that aim to enhance the host's immune response against viral infection and hinder critical virus-host interactions. (archivog.com)
  • Cervical cancer (CC) kills a 250,000 people annually, frequently affecting young women, and requires persistent infection with high-risk Human Papillomavirus (hrHPV) for its development. (prescriptec.org)
  • HPV OncoPredict is an innovative diagnostic device (IVD) capable of detecting all oncogenic hrHPV genotypes frequently causing cervical infection as well as allowing to accurate identification those 10% of infected women who are truly at risk of developing cervical cancer. (prescriptec.org)
  • Although most human papillomavirus (HPV) infections are transient and disappear within a few years of exposure, 10%-20% of infections persist latently, leading to disease progression, and ultimately various forms of invasive cancer. (archivog.com)
  • Studies have shown the potential protective effect of neutralizing antibodies against subsequent infections when the immune response is initiated by HPV vaccines [ 10 ]. (biomedcentral.com)
  • Despite the optimism that has accompanied the introduction of prophylactic vaccines to prevent some HPV infections, the relatively modest uptake of the vaccine, especially in the developing world, and the very high fraction of men and women who are already infected, means that HPV-associated disease will remain as a significant public health problem for decades. (virosin.org)
  • Vaccines offer the potential to prime a pathogen-specific immune response and subsequently reduce disease burden. (smw.ch)
  • The vaccine-induced immune response is influenced by: (i.) vaccine factors i.e., type and composition of the antigen(s), (ii. (smw.ch)
  • Assessment of humoral immune responses following human papillomavirus (HPV) vaccination currently relies on invasive blood sampling. (cdc.gov)
  • cAD3-Marburg is a vaccine candidate inducing immune responses against the Marburg virus. (precisionvaccinations.com)
  • CoVepiT is a prophylactic vaccine candidate against COVID-19 based on optimized peptides selected to induce a lasting sentinel T lymphocyte immune response against SARS-CoV-2 in barrier tissues such as the respiratory tract and the lung. (precisionvaccinations.com)
  • The features including targeting cancer-related factors Rb and p53, the ability of cellular transformation "in vitro", encoding proteins with oncogenic functions such as IE and pp65, employing mechanisms of oncomodulation and evading the immune system responses, have turned HCMV into an influential factor involved in pathogenesis of human malignancies, such as glioma, neuroblastoma, and breast cancer [10-11]. (waocp.com)
  • Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease por: Joura, Elmar A., et al. (ccb.org.co)
  • The neutralizing antibodies elicited by human papillomavirus (HPV) major capsid protein L1 virus-like particle (VLP)-based vaccines are largely type-specific. (oncotarget.com)
  • Encouraging information, counseling and continuing education is recommended as a strategy to broaden vaccine acceptance in order to sediment its implementation and ensure effectiveness in reducing new cases of cervical cancer in the future. (bvsalud.org)
  • The clinical history and presentation of human papillomavirus (HPV) infection vary according to the anatomic area involved. (medscape.com)
  • Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine por: Ault K.A., et al. (ccb.org.co)
  • Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. (virosin.org)
  • 7 8 Both vaccines have the potential to bring a decrease in the incidence of human papillomavirus related disease and are being considered for routine immunisation in many countries. (bmj.com)
  • More research is needed, particularly regarding the incidence of vaccine-preventable infectious diseases and the safety of vaccination in patients with AIIRD. (bmj.com)
  • Understanding the role of naturally acquired (i.e., infection-induced) human papillomavirus (HPV) antibodies against reinfection is important given the high incidence of this sexually transmitted infection. (biomedcentral.com)
  • Vaccination against Human Papilloma Virus (HPV) may help to reduce the incidence of cervical cancer. (biomedcentral.com)
  • Key questions were formulated and the eligible spectrum of AIIRD, immunosuppressive drugs and vaccines were defined in order to perform a systematic literature review. (bmj.com)
  • The Gardasil Access Program provides HPV vaccine at no cost to help national institutions gain experience implementing HPV vaccination. (biomedcentral.com)
  • These results suggest that behavioral health factors may be associated with vaccine acceptability and further our understanding of how behavioral patterns may contribute to the uptake of new cancer prevention strategies. (aacrjournals.org)
  • In 2006, the U.S. Food and Drug Administration (FDA) approved the first HPV vaccine for administration to females 9 to 26 years of age for the prevention of cervical cancer ( 5, 6 ). (aacrjournals.org)
  • This guideline on human papillomavirus (HPV) in individuals with HIV was developed by the New York State Department of Health AIDS Institute (NYSDOH AI) to inform primary care providers and other practitioners in New York State about HPV prevention, screening methods, diagnosis and presentation, and treatment in adults with HIV. (hivguidelines.org)
  • Vaccines can work as primary prevention in healthy people to reduce premalignant and cancer occurrence and as tertiary prevention for cancer patients who received curative treatment to reduce recurrence. (jci.org)
  • CodaVax RSV is an intranasal, live-attenuated vaccine candidate for the prevention of respiratory syncytial virus. (precisionvaccinations.com)
  • The present review describes various oncogenic mechanisms of HPV infection at the level of the host cell genome. (archivog.com)
  • To avoid elimination by this mechanism, human papillomaviruses (HPV) have developed several mechanisms that enable the cells they infect to elude both extrinsic and intrinsic apoptosis. (mdpi.com)
  • In this review we use influenza vaccine as a model in a discussion of the different mechanisms of action of the available adjuvants. (smw.ch)
  • This cross-sectional study describes the age-specific prevalence of human papillomavirus (HPV) infection and cytological abnormalities among this urban and peri-urban population. (samj.org.za)
  • Specifically, the patent was granted for the therapeutic use of intradermally delivered long peptides derived from the E2, E6 and/or E7 proteins of the human papillomavirus (HPV) to treat or prevent HPV-related diseases. (akampion.com)
  • In addition, antibody responses to the vaccine are higher before the onset of puberty. (nursinginpractice.com)
  • Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus. (oncotarget.com)
  • Thus, despite the low consumable cost, high quality cytology is expensive in absolute terms and may not necessarily be the most cost-effective option for screening.4 Chronic infection with oncogenic HPV is a necessary, but insufficient cause for the development of cervical cancer. (ijcrr.com)
  • The first few years of the project provided key information, including data on HPV type distribution, before expected effect of vaccine introduction. (cdc.gov)
  • The World Health Organization (WHO) has underscored the importance of screening, stating that "the introduction of HPV vaccine should not undermine or divert funding from effective screening programmes for cervical cancer" (WHO, 2009). (medscinet.com)
  • An HPV vaccine inducing cross-neutralizing antibodies broadly will be cost-effective and of great value. (oncotarget.com)
  • The 9-valent vaccine was licensed in 2014, and in February 2015, ACIP included it as one of 3 recommended HPV vaccines ( 5 ). (cdc.gov)
  • During April 2018-June 2019, the ACIP HPV Vaccines Work Group held at least monthly conference calls to review and discuss relevant scientific evidence regarding adult HPV vaccination using the Evidence to Recommendations framework. (cdc.gov)
  • There are five different genera of papillomaviruses found in humans - Alpha, Beta, Gamma, Mu, and Nu - classified according to DNA sequence analysis, and showing different life cycle characteristics and disease associations. (unesp.br)
  • Curevo CRV-101 is a vaccine designed to maximize CMI protection by combining the gE protein antigen with a proprietary adjuvant. (precisionvaccinations.com)
  • Through the incorporation of novel computational methods for predicting antigen changes to model-informed drug discovery and development, superior vaccines and antibody-based therapeutics or diagnostics can now be more easily designed to mitigate failures. (preprints.org)
  • This trend, suggestive of a resurgence in cervical cancer, has also been observed in many European countries and could reflect increased cancer detection by the use of new diagnostic techniques, such as human papillomavirus (HPV) testing and cervicography, or it could be the result of a cohort effect. (cmaj.ca)
  • Lutz Gissmann is known for his seminal research in the field of human papillomaviruses (HPV) and their causal association with human cancer, especially cervical cancer. (wikipedia.org)
  • So far, vaccines have made more progress in preventing cancer than in eliminating already established cancer. (jci.org)
  • and address various issues related to maximizing cancer vaccine benefit. (jci.org)
  • Model for prophylactic cancer vaccine. (jci.org)
  • According to the World Health Organization, human papillomavirus (HPV) causes cervical cancer, which is the fourth most common cancer in women, with an estimated 266,000 deaths and 528,000 new cases in 2012. (phmj.org)
  • 2011. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. (virosin.org)
  • Papillomaviruses: Viral evolution, cancer and evolutionary medicine. (virosin.org)
  • Women accessing the public health system in Gauteng province, South Africa are largely unscreened for cervical cancer and have a high background prevalence of human immunodeficiency virus (HIV) infection. (samj.org.za)
  • A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses. (unipr.it)
  • Prior studies have examined demographic, medical history, and psychosocial variables associated with parental HPV vaccine acceptability, although few have investigated the behavioral correlates of vaccine acceptability. (aacrjournals.org)
  • The primary purpose of the current study is to report on national acceptability of the HPV vaccine among U.S. adults with female children in the household and to investigate the health behavior correlates of vaccine acceptability. (aacrjournals.org)
  • Currently, several prophylactic vaccines are available, which include: bivalent vaccines that offer protection against HPV-16/18, quadrivalent vaccines against HPV-6/11/16/18, and nonavalent vaccines against HPV-6/11/16/18/31/33/45/52/58 [ 11 ]. (biomedcentral.com)
  • Vaccine Uptake Rate (VUR) and Vaccine Adherence between the first and third doses (VA) rate were calculated. (biomedcentral.com)
  • In this study, 58 women receiving three doses of the 9vHPV vaccine within a Gardasil9 (9vHPV) Phase III randomized controlled trial were included. (cdc.gov)
  • Vaccination is also recommended for persons at increased risk of severe vaccine-preventable disease. (smw.ch)
  • ISA101, a novel immunotherapeutic consisting of synthetic long peptides (SLP®s), targets severe diseases triggered by human papillomavirus (HPV) infection. (akampion.com)
  • 5 In 2008, the HPV vaccination programme was introduced in the UK for girls aged 12 to 13, with catch-up programmes aiming to offer the vaccine to all girls born on or after September 1 1990. (nursinginpractice.com)
  • 2006. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. (virosin.org)
  • Many current nonadjuvanted vaccines are poorly effective in the elderly and immunocompromised populations, resulting in nonprotective postvaccine antibody titres, which serve as surrogate markers for protection. (smw.ch)